Abstract
Nonspecific immunostimulation with mycobacterial agents, especially BCG, have been widely utilized (1) in an effort to increase host resistance to malignancy. Crude viable and/or killed mycobacterial agents are heterogenous preparations (2, 3), which have a significant incidence of morbidity. From an immunotherapeutic viewpoint, BCG has been shown (4, 5), in high doses, to cause splenic suppressor cells in mice, and has been implicated in causing tumor enhancement (6). Because of these problems, major interest has centored on the purification and use of microbial components.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bast, R. C., B. Zbar, T. Boros, and H. G. Rapp. 1974. BCG and cancer. N. Engl. J. Med. 290: 1413–1419.
Aungst, C. W., J. E. Sokol, and B. V. Jager. 1975. Complications of BCG vaccination in neoplastic disease. Ann. Int. Med. 82: 666–669.
McKhann, C. F., C. G. Hendrickson, L. E. Spitler, A. Gunnarson, D. Bannerjee, and W. R. Nelson. 1975. Immunotherapy of melanoma with BCG–two fatalities following intralesional injection. Cancer 35: 514–520.
Florentin, I., R. Huchet, M. Bruley-Rosset, O. Halle-Pannenko and G. Mathe. 1976. Studies on the mechanism of action of BCG. Cancer Immunol. Immunother. 1: 31–39.
Gefford, M., and S. Orbach-Arbuoys. 1976. Enhancement of T suppressor activity in mice by high doses of BCG. Cancer Immunol. Immunother. 1: 41–45.
Bornstein, R. R., M. J. Mastrangelo, N. Sulit, D. Chee, J. W. Yarboro, L. Prehn, and R. J. Prehn. 1973. Immunotherapy of melanoma with intralesional BCG. Nat. Cancer Inst. Monog. 39: 213–215.
McLaughlin, C. A., S. M. Strain, W. D. Bickel, M. B. Goren, K. Azuma, K. Milner, J. L. Cantrell, and E. Ribi. 1978. Regression of line 10 hepatocellular carcinomas following treatment with water-soluble microbial extracts combined with trehalose or arabinose mycolates. Cancer Immunol. Immunother. 4: 61–68.
Milas, L., N. Hunter, and H. R. Withers. 1975. Combination of local irradiation with systemic applications of anaerobic corynebacterium in therapy of a murine fibrosarcoma. Cancer Res. 35: 1274–1277.
Vosika, G. J., J. Schmidtke, A. Goldman, E. Ribi, R. Parker, and G. R. Gray. 1979. Intralesional immunotherapy of malignant melanoma with mycobacterium smegmatis cell wall skeleton combined with trehalose dimycolate. Cancer 44: 495–503.
Vosika, G. J., J. Schmidtke, A. Goldman, E. Ribi, and G. R. Gray. 1979. Phase I-II study of intralesional immunotherapy with oil-attached mycobacterium smegmatis cell wall skeleton and trehalose dimycolate. Cancer Immunol. Immunother. 6: 135–142.
Halpern, B. (ed.). 1975. Corynebacterium parvum: Applications in experimental and clinical oncology. Plenum Press, New York.
Azuma, I., E. Ribi, T. J. Meyer, and B. Zbar. 1974. Biologically active components of mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J. Nat. Cancer Inst. 52: 95–101.
Gray, G. R., E. Ribi, D. Granger, R. Parker, I. Azuma, and K. Yamomoto. 1975. Immunotherapy of cancer: Tumor suppression and regression by cell walls of mycobacterium phlei attached to oil droplets. J. Nat. Cancer Inst. 55: 727–730.
Ribi, E., M. C. Milner, D. Granger, M. T. Kelly, K. Yamomoto, W. Brehmer, R. Parker, R. F. Smith, and S. M. Strain. 1976. Immunotherapy with non-viable microbial components. Ann. N. Y. Acad. Sci. 277: 228–238.
Israel, L., R. Edelstein, A. DePierre, and N. Dimitrov. 1975. Daily intravenous infusion of corynebacterium parvum in twenty patients with disseminated cancer. A preliminary report of clinical and biological findings. J. Nat. Cancer Inst. 55: 29–33.
Vosika, G. J., Schmidtke, A. Goldman, E. Ribi, R. Parker, and G. R. Gray. 1978. Local and systemic immunotherapy of human cancer with mycobacterial cell wall skeleton and trehalose dimycolate (P3), p. 33–51. In E. M. Hersh, M. A. Chirigos and M. J. Mastrangelo (eds.), Augmenting agents in cancer therapy. Raven Press, New York, N. Y.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vosika, G., Trenbeath, T., Giddings, C., Gray, G.R. (1983). Clinical Phase I Investigation of Intravenous Oil Attached Mycobacterial Components as Immunotherapeutic Agents. In: Klein, T., Specter, S., Friedman, H., Szentivanyi, A. (eds) Biological Response Modifiers in Human Oncology and Immunology. Advances in Experimental Medicine and Biology, vol 166. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-1410-4_13
Download citation
DOI: https://doi.org/10.1007/978-1-4757-1410-4_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-1412-8
Online ISBN: 978-1-4757-1410-4
eBook Packages: Springer Book Archive